Major grant advances pioneering melanoma therapy at NeoStem
NeoStem announced it will receive $17.7 million grant from the CIRM to support its pioneering treatment for patients with stage III recurrent or stage IV metastatic melanoma, a potentially breakthrough approach that teaches the immune system which cells to attack and kill. May 21, 2015